Matthew W. Foehr

2015 - Ligand Pharmaceuticals

In 2015, Matthew W. Foehr earned a total compensation of $3.4M as President and Chief Operating Officer at Ligand Pharmaceuticals, a 17% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$196,000
Option Awards$1,356,995
Salary$410,472
Stock Awards$1,250,322
Other$143,501
Total$3,357,290

Foehr received $1.4M in option awards, accounting for 40% of the total pay in 2015.

Foehr also received $196K in non-equity incentive plan, $410.5K in salary, $1.3M in stock awards and $143.5K in other compensation.

Rankings

In 2015, Matthew W. Foehr's compensation ranked 2,732nd out of 13,638 executives tracked by ExecPay. In other words, Foehr earned more than 80.0% of executives.

ClassificationRankingPercentile
All
2,732
out of 13,638
80th
Division
Manufacturing
963
out of 5,190
81st
Major group
Chemicals And Allied Products
351
out of 1,854
81st
Industry group
Drugs
275
out of 1,528
82nd
Industry
Pharmaceutical Preparations
217
out of 1,182
82nd
Source: SEC filing on April 14, 2017.

Foehr's colleagues

We found five more compensation records of executives who worked with Matthew W. Foehr at Ligand Pharmaceuticals in 2015.

2015

John Higgins

Ligand Pharmaceuticals

Chief Executive Officer

2015

Matthew Korenberg

Ligand Pharmaceuticals

Chief Financial Officer

2015

Nishan de Silva

Ligand Pharmaceuticals

Chief Financial Officer

2015

Charles Berkman

Ligand Pharmaceuticals

General Counsel

2015

Melanie Herman

Ligand Pharmaceuticals

Chief Financial Officer

News

You may also like